Institut Curie selects RayStation for proton planning
RaySearch Laboratories AB (publ) is pleased to announce that Institut Curie, spread over three radiotherapy centers, located in Paris, Orsay, and Saint-Cloud, France, has placed an order for the treatment planning system RayStation®*. Institut Curie is part of the French hospital network Unicancer, and the order was placed under the Unicancer 2019 Framework agreement.
RayStation will mainly support the Institut Curie Proton Therapy Center in Orsay, which is one of three proton centers in France, all of which are now equipped with RayStation.
The purchase will give Institut Curie access to advanced RayStation technology such as LET optimization, adaptive planning and AI autocontouring capabilities, for both proton and photon treatment planning.
Régis Ferrand, Head of Physics, Institut Curie, says: “Advanced key tools available in the RaySearch environment will help us bring our proton treatments to the highest quality.”
Johan Löf, founder and CEO, RaySearch, says: “We are proud of our collaboration with Institut Curie, a well-reputed hospital with an impressive legacy. The agreement is a first step; I look forward to deepening our relationship and to a fruitful collaboration.”
The total order value is about 1.7 MEUR excluding service agreement, of which the majority has been recognized as revenue in the third quarter of 2024.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Learn more about us on:
About Institut Curie
Institut Curie is France’s largest cancer research center and among the very best in Europe. It combines renowned research facilities with a cutting-edge hospital group to deliver excellence in clinical care. Institut Curie treats all types of cancers, even the rarest, and also serves as a Center of Excellence in Europe for breast cancer, as well as for pediatric cancers, eye tumors, and sarcomas. Founded in 1909 by Marie Curie, Institut Curie encompasses three sites (Paris, Saint-Cloud and Orsay) with more than 3,800 researchers, doctors, and caregivers, all sharing the common missions of research, excellence in clinical care, and sharing knowledge, to accelerate innovation in the fight against cancer and provide cutting-edge treatment to patients. For more information: institut-curie.org.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 1,000 clinics in 44 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
Tags:
